IMOMA: Instituto de Medicina Oncológica y Molecular de Asturias 

Síguenos en twitter siguenos_facebook facebook

Highlights 2 columns

ONCOgenics Tumor

ONCOGenics Tumor
Paso 1

Ask your oncologist for ONCOgenics Tumor

Paso 2

Your oncologist sends your tumor sample to our laboratory

Paso 3

We extract DNA from your tumor and analyse it to detect all of the alterations related to approved cancer therapies

Paso 4

We write up a report for your oncologist, detailing all of the identified alterations and outlining all of the personalised therapies available for your particular case

ONCOgenics Tumor is not a conventional analysis. Conventional analyses only evaluate one or a few genes.

ONCOgenics Tumor analyses all gene alterations related to targeted therapies which have been approved for cancer treatment. These therapies are designed to be more effective and less toxic than conventional treatments, by directly targeting the cancer’s weak links.

ONCOgenics Tumor will allow you to find out if your tumor contains any of these weak links, in order to select the best treatment.

ONCOGenics Easy

Our genomic sequencing services are the fruit of years of research and expertise. At IMOMA we are pioneers in carrying out genomic analyses for diagnosing and selecting personalised treatments:


First tumor exome derived from frozen tissue, in order to select a targeted treatment


Identification, using exomes, of Néstor and Guillermo Progeria Syndrome, a new accelerated aging syndrome (published in the American Journal of Medical Genetics A and the American Journal of Human Genetics)


Identification, using exomes, of new tumor suppressors in laryngeal cancer (published in Nature Communications)


First tumor exome derived from paraffin embedded tissue, for selection of targeted treatment


Launch of ONCOGenics Tumor: sequencing of tumors embedded in paraffin for selecting approved targeted cancer therapies (a service developed in collaboration with DREAMgenics)

Más sobre OncoGenicsTumor
ONCOgenics Tumor complements the molecular diagnosis of cancer. It is aimed at the identification of all genetic alterations which may confer sensitivity or resistance to cancer drugs approved for clinical use.
This test analyses the DNA sequence of more than 80 genes and the presence/absence of more than 10 genetic rearrangements of clinical relevance, using paraffin embedded tumor tissue.
ONCOgenics Tumor uses bioinformatic tools, exclusive to  DREAMgenics and validated by several internationally recognised scientific publications (references DREAMgenics), with analytical sensitivity and specificity above 99%.
Resultados ONCOgenics Easy
The results are outlined to the patient’s doctor in a detailed report (3-4 pages) including the identified alterations, their description and the related therapeutic implications, providing the doctor with the necessary information to select the best treatment for the patient. Furthermore, the information obtained through this test facilitates participation in "basket" type clinical trials, specifically directed towards the tumor’s molecular alterations instead of its histology.


For more detailed information we invite you to consult the following information brochure (click on the image to download):


<< volver

  • Compartir en:
    • facebook (en nueva ventana)
    • twitter (en nueva ventana)
    • google bookmarks (en nueva ventana)